Azithromycin does not improve disease severity in acute experimental pancreatitis

• DOI: 10.1371/journal.pone.0216614
• Publication Date: 2019-05-10T17:27:03Z
• Authors: Sebastian Weis; Mario Heindl; Tania Carvalho; Elisa Jentho; Jana Lorenz; Ines Sommerer; Joachim Mössner; Albrecht Hoffmeister
• Keywords: Pathogenesis; Pancreatic Disease

Acute pancreatitis is a severe systemic disease triggered by sterile inflammation and initial local tissue damage of the pancreas. Immune cells infiltrating into pancreas are main mediators acute pathogenesis. In addition to their antimicrobial potency, macrolides possess anti-inflammatory immunomodulatory properties which routinely used in patients with chronic airway infections might also beneficial treatment lung injury. We here tested hypothesis that macrolide antibiotic azithromycin can improve course experimental via ameliorating imposed inflammation, could be as specific therapy. However, our data show does not have influence on caerulein induced terms reduction organ damage, severity. Furthermore Infiltration immune or lungs was attenuated compared controls ampicillin treated animals pancreatitis. conclude chosen model, any effects its cannot decrease severity model caerulein-induced mice.